A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 144 results

Nathan Clumeck, Jean Michel Molina, Keith Henry, Joseph Gathe, Jürgen K. Rockstroh, Edwin Dejesus, Xuelian Wei, Kirsten White, Marshall W. Fordyce, Martin S. Rhee, Javier Szwarcberg

Research output: Contribution to journal › Letter › peer-review

77 Scopus citations

Fingerprint

Dive into the research topics of 'A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 144 results'. Together they form a unique fingerprint.